A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment
NCT03812835 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2021-11-11
Summary
Number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with apixaban, according to therapeutic indications approved in Mexico.
Conditions
- Thrombosis, Deep Vein
- Pulmonary Embolism
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-08-23
- Primary Completion
- 2023-08-23
- Completion
- 2023-08-23
More Related Trials
-
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
NCT01583218 ·Status: COMPLETED ·Phase: PHASE3
-
AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients
NCT01780987 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
NCT04041843 ·Status: COMPLETED ·Phase: PHASE2
-
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
NCT02464969 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
NCT01707394 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
NCT00252005 ·Status: COMPLETED ·Phase: PHASE2
-
Calf Deep Vein Thrombosis Treatment Trial
NCT03590743 ·Status: TERMINATED ·Phase: PHASE4
-
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00371683 ·Status: COMPLETED ·Phase: PHASE3
-
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
NCT03404635 ·Status: COMPLETED
-
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
NCT00423319 ·Status: COMPLETED ·Phase: PHASE3
-
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
NCT03988842 ·Status: TERMINATED ·Phase: PHASE4
-
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
NCT04168203 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation
NCT03489395 ·Status: COMPLETED ·Phase: PHASE2
-
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
NCT03456648 ·Status: COMPLETED ·Phase: PHASE2
-
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
NCT02295475 ·Status: COMPLETED ·Phase: PHASE4
-
Apixaban for Extended Anticoagulation (APIDULCIS)
NCT03678506 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot
NCT03521908 ·Status: COMPLETED
-
Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus
NCT02982590 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
NCT00787150 ·Status: COMPLETED ·Phase: PHASE2
-
Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden
NCT02492828 ·Status: COMPLETED
-
Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients
NCT02048865 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
NCT03266783 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
NCT00443053 ·Status: COMPLETED ·Phase: PHASE3
-
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00452530 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
NCT02559856 ·Status: COMPLETED ·Phase: PHASE4